



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

BC HIV Treatment Program

Monthly Report
March 2025



FOREWORD

The British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) is a provincial treatment and research program, with the mandate to improve the health of people living with HIV (“PLWH”), and those at elevated risk of acquiring HIV in British Columbia (BC), by advancing and promoting programs for treatment and prevention of HIV, and related conditions, guided by Treatment as Prevention® (TasP®) principles. Funded by the BC’s Ministry of Health, through the province’s PharmaCare Program, the BC-CfE’s Drug Treatment Programs provide medications for HIV treatment, prevention, and select related conditions, at no charge, to medically eligible BC residents living with HIV, or at elevated risk of HIV acquisition. The provision of these medications are based on guidelines developed by the BC-CfE’s Committee for Drug Evaluation and Therapy (CDET) and program consideration.

A key component of the BC-CfE’s mandate is to monitor and evaluate its HIV Treatment Program, reporting on a regular basis and providing essential information to BC’s health authorities, treating clinicians, and the community at large. This HIV Treatment Program Report provides an overview of the use of antiretroviral medications in BC for the treatment of HIV, common drug combinations, key monitoring parameters, and distribution of program participants throughout the province.

Figures and graphs in this document are best viewed in colour.

Please note that any comments or queries regarding this report should be forwarded to info@bccfe.ca.

BC Centre for Excellence in HIV/AIDS Drug Treatment Programs

St. Paul’s Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through BC’s PharmaCare and Ministry of Health.

DISCLAIMER: All information presented in this report is generated from a secure, live database maintained by the BC-CfE. Privacy and confidentiality are matters which are taken very seriously and strict rules and procedures are applied to ensure that the information stored is secure.

Figures and tables provided in this report represent the best estimates at the time the document was generated, and may be subject to change. Please be advised that the information in this document is provided in good faith and is derived from sources understood to be accurate and up-to-date at the report’s date of publication.

© 2026 BC Centre for Excellence in HIV/AIDS



TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.3 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
- 1.7 Number of Participants on Protease Inhibitors by INGREDIENT
- 1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
- 1.11 Number of Participants on Integrase Inhibitors by INGREDIENT
- 1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (graph)
- 1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (table)
- 1.16 Percent Distribution of Active Participants by CD4 Count
- 1.17 Distribution of Active Participants by CD4 Count
- 1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (graph)
- 1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (table)
- 1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (graph)
- 1.21 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (table)
- 1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (graph)
- 1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (table)
- 1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance (graph)
- 1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance (table)

2. List of Tables

- 2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of January 2025
- 2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment
- 2.3 BC-CfE HIV Treatment Program Enrolment

3. Distribution of HIV Treatment Program Active Participants

- 3.1 Provincial Health Authorities
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

TABLE OF CONTENTS (continued)

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants by Age & Sex at Birth
- 4.2 Distribution of Participants by Program Duration
- 4.3 Distribution of Antiretroviral Treatment Prescribers

FRASER HEALTH

- 4.4 Distribution of Participants by Age & Sex at Birth
- 4.5 Distribution of Participants by Program Duration
- 4.6 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER COASTAL

- 4.7 Distribution of Participants by Age & Sex at Birth
- 4.8 Distribution of Participants by Program Duration
- 4.9 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER ISLAND

- 4.10 Distribution of Participants by Age & Sex at Birth
- 4.11 Distribution of Participants by Program Duration
- 4.12 Distribution of Antiretroviral Treatment Prescribers

NORTHERN HEALTH


- 4.13 Distribution of Participants by Age & Sex at Birth
- 4.14 Distribution of Participants by Program Duration
- 4.15 Distribution of Antiretroviral Treatment Prescribers

INDIGENOUS PARTICIPANTS

- 4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth



1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
March 2025
N = 7689




Health Authority	Male	Female	All
FRASER	1614	502	2116
VANCOUVER ISLAND	885	176	1061
VANCOUVER COASTAL	3191	449	3640
INTERIOR	494	118	612
NORTHERN	169	80	249
	6353	1325	7678
Unknown/not stated			11
Total			7689

On antiretroviral treatment is defined as being on treatment in the current month
Unknown/not stated is defined as being on treatment in the current month, and city of residence is unknown
Male & Female refer to Sex assigned at birth



1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
March 2020 - March 2025



1.3 Distribution of Participants in HIV Treatment Program by Regimen Category

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
APR-2023	7553	4736	62.7	704	9.3	653	8.6	762	10.1	634	8.4	64	0.8
MAY-2023	7592	4752	62.6	706	9.3	644	8.5	800	10.5	627	8.3	63	0.8
JUN-2023	7599	4788	63.0	675	8.9	625	8.2	819	10.8	627	8.3	65	0.9
JUL-2023	7577	4758	62.8	662	8.7	626	8.3	842	11.1	628	8.3	61	0.8
AUG-2023	7600	4773	62.8	643	8.5	621	8.2	864	11.4	632	8.3	67	0.9
SEP-2023	7609	4793	63.0	639	8.4	616	8.1	879	11.6	617	8.1	65	0.9
OCT-2023	7610	4808	63.2	615	8.1	611	8.0	897	11.8	618	8.1	61	0.8
NOV-2023	7612	4799	63.0	611	8.0	599	7.9	918	12.1	624	8.2	61	0.8
DEC-2023	7603	4808	63.2	593	7.8	596	7.8	936	12.3	614	8.1	56	0.7
JAN-2024	7642	4856	63.5	583	7.6	585	7.7	952	12.5	609	8.0	57	0.7
FEB-2024	7647	4861	63.6	564	7.4	586	7.7	971	12.7	609	8.0	56	0.7
MAR-2024	7636	4846	63.5	543	7.1	580	7.6	991	13.0	618	8.1	58	0.8
APR-2024	7670	4884	63.7	538	7.0	570	7.4	1000	13.0	621	8.1	57	0.7
MAY-2024	7687	4902	63.8	536	7.0	566	7.4	1023	13.3	607	7.9	53	0.7
JUN-2024	7687	4910	63.9	526	6.8	556	7.2	1033	13.4	606	7.9	56	0.7
JUL-2024	7718	4938	64.0	520	6.7	541	7.0	1060	13.7	605	7.8	54	0.7
AUG-2024	7709	4933	64.0	505	6.6	537	7.0	1081	14.0	602	7.8	51	0.7
SEP-2024	7697	4911	63.8	484	6.3	530	6.9	1124	14.6	595	7.7	53	0.7
OCT-2024	7725	4938	63.9	467	6.0	512	6.6	1167	15.1	593	7.7	48	0.6
NOV-2024	7703	4946	64.2	464	6.0	490	6.4	1176	15.3	581	7.5	46	0.6
DEC-2024	7720	4949	64.1	456	5.9	479	6.2	1199	15.5	588	7.6	49	0.6
JAN-2025	7739	4959	64.1	437	5.6	478	6.2	1234	15.9	586	7.6	45	0.6
FEB-2025	7696	4929	64.0	419	5.4	460	6.0	1264	16.4	577	7.5	47	0.6
MAR-2025	7689	4921	64.0	408	5.3	453	5.9	1291	16.8	572	7.4	44	0.6

n is number of participants on the specified regimen class in the specified month


% is ratio of **n** and total number of participants on antiretroviral treatment in the specified month

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
March 2020 - March 2025




1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	abacavir		emtricitabine		lamivudine		tenofovir <TAF>		tenofovir <TDF>		zidovudine	
		n	%	n	%	n	%	n	%	n	%	n	%
APR-2023	7418	2067	27.9	4469	60.3	2948	39.7	3550	47.9	1030	13.9	15	0.2
MAY-2023	7451	2043	27.4	4513	60.6	2940	39.5	3598	48.3	1040	14.0	16	0.2
JUN-2023	7460	2008	26.9	4533	60.8	2934	39.3	3655	49.0	1002	13.4	14	0.2
JUL-2023	7438	1966	26.4	4530	60.9	2917	39.2	3678	49.5	985	13.2	14	0.2
AUG-2023	7467	1935	25.9	4561	61.1	2909	39.0	3717	49.8	969	13.0	14	0.2
SEP-2023	7478	1910	25.5	4578	61.2	2902	38.8	3746	50.1	954	12.8	13	0.2
OCT-2023	7474	1895	25.4	4573	61.2	2904	38.9	3766	50.4	935	12.5	14	0.2
NOV-2023	7474	1866	25.0	4585	61.4	2891	38.7	3783	50.6	918	12.3	15	0.2
DEC-2023	7464	1831	24.5	4595	61.6	2874	38.5	3820	51.2	895	12.0	13	0.2
JAN-2024	7502	1831	24.4	4633	61.8	2881	38.4	3866	51.5	890	11.9	13	0.2
FEB-2024	7504	1795	23.9	4641	61.9	2868	38.2	3896	51.9	864	11.5	13	0.2
MAR-2024	7493	1759	23.5	4656	62.1	2845	38.0	3927	52.4	844	11.3	13	0.2
APR-2024	7525	1742	23.2	4690	62.3	2844	37.8	3968	52.7	843	11.2	13	0.2
MAY-2024	7544	1706	22.6	4734	62.8	2822	37.4	4018	53.3	832	11.0	12	0.2
JUN-2024	7544	1691	22.4	4738	62.8	2817	37.3	4047	53.7	801	10.6	13	0.2
JUL-2024	7570	1667	22.0	4763	62.9	2812	37.2	4077	53.9	800	10.6	13	0.2
AUG-2024	7563	1633	21.6	4771	63.1	2796	37.0	4097	54.2	782	10.3	13	0.2
SEP-2024	7551	1600	21.2	4769	63.2	2797	37.0	4113	54.5	768	10.2	13	0.2
OCT-2024	7577	1556	20.5	4810	63.5	2789	36.8	4170	55.0	754	10.0	13	0.2
NOV-2024	7555	1499	19.8	4821	63.8	2744	36.3	4193	55.5	739	9.8	11	0.2
DEC-2024	7572	1481	19.6	4835	63.9	2756	36.4	4223	55.8	734	9.7	11	0.2
JAN-2025	7591	1431	18.9	4873	64.2	2740	36.1	4273	56.3	721	9.5	10	0.1
FEB-2025	7547	1370	18.2	4860	64.4	2698	35.8	4280	56.7	701	9.3	8	0.1
MAR-2025	7537	1335	17.7	4869	64.6	2680	35.6	4312	57.2	684	9.1	8	0.1

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
March 2020 - March 2025




1.7 Number of Participants on Protease Inhibitors by INGREDIENT

MON-YYYY	Total Participants	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
		n	%	n	%	n	%	n	%	n	%
APR-2023	1301	305	23.4	957	73.6	41	3.2	1	0.1	1	0.1
MAY-2023	1291	303	23.5	951	73.7	39	3.0	1	0.1	1	0.1
JUN-2023	1267	294	23.2	936	73.9	39	3.1	1	0.1	1	0.1
JUL-2023	1247	283	22.7	927	74.3	38	3.1	1	0.1	1	0.1
AUG-2023	1225	276	22.5	914	74.6	36	2.9	0	0.0	0	0.0
SEP-2023	1214	271	22.3	909	74.9	35	2.9	0	0.0	0	0.0
OCT-2023	1198	273	22.8	893	74.5	35	2.9	0	0.0	0	0.0
NOV-2023	1184	260	22.0	890	75.2	35	3.0	0	0.0	0	0.0
DEC-2023	1156	248	21.5	876	75.8	33	2.9	0	0.0	0	0.0
JAN-2024	1138	241	21.2	866	76.1	33	2.9	0	0.0	0	0.0
FEB-2024	1111	229	20.6	852	76.7	31	2.8	0	0.0	0	0.0
MAR-2024	1094	225	20.6	840	76.8	30	2.7	0	0.0	0	0.0
APR-2024	1088	224	20.6	835	76.8	31	2.9	0	0.0	0	0.0
MAY-2024	1081	221	20.4	828	76.6	33	3.1	0	0.0	0	0.0
JUN-2024	1059	214	20.2	813	76.8	33	3.1	0	0.0	0	0.0
JUL-2024	1052	216	20.5	805	76.5	33	3.1	0	0.0	0	0.0
AUG-2024	1021	208	20.4	784	76.8	31	3.0	0	0.0	0	0.0
SEP-2024	1001	203	20.3	772	77.1	27	2.7	0	0.0	0	0.0
OCT-2024	977	197	20.2	754	77.2	27	2.8	0	0.0	0	0.0
NOV-2024	957	190	19.9	742	77.5	28	2.9	0	0.0	0	0.0
DEC-2024	947	184	19.4	738	77.9	26	2.8	0	0.0	0	0.0
JAN-2025	922	177	19.2	726	78.7	23	2.5	0	0.0	0	0.0
FEB-2025	891	168	18.9	700	78.6	24	2.7	0	0.0	0	0.0
MAR-2025	875	167	19.1	686	78.4	24	2.7	0	0.0	0	0.0

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Ritonavir - greater than 400 mg total daily dose

1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
March 2020 - March 2025




1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	doravirine n %	efavirenz n %	etravirine n %	nevirapine n %	rilpivirine n %
APR-2023	970	215 22.2	232 23.9	96 9.9	245 25.3	187 19.3
MAY-2023	977	223 22.8	232 23.8	98 10.0	239 24.5	187 19.1
JUN-2023	954	224 23.5	228 23.9	96 10.1	230 24.1	180 18.9
JUL-2023	953	235 24.7	222 23.3	94 9.9	225 23.6	178 18.7
AUG-2023	951	238 25.0	222 23.3	91 9.6	223 23.5	182 19.1
SEP-2023	938	236 25.2	218 23.2	88 9.4	220 23.5	177 18.9
OCT-2023	932	238 25.5	216 23.2	89 9.6	220 23.6	173 18.6
NOV-2023	928	242 26.1	209 22.5	88 9.5	219 23.6	173 18.6
DEC-2023	929	250 26.9	205 22.1	87 9.4	213 22.9	176 19.0
JAN-2024	921	250 27.1	200 21.7	83 9.0	208 22.6	181 19.7
FEB-2024	919	257 28.0	192 20.9	82 8.9	207 22.5	182 19.8
MAR-2024	914	260 28.5	190 20.8	80 8.8	205 22.4	181 19.8
APR-2024	915	261 28.5	190 20.8	82 9.0	203 22.2	180 19.7
MAY-2024	906	262 28.9	186 20.5	80 8.8	205 22.6	175 19.3
JUN-2024	893	262 29.3	182 20.4	79 8.9	198 22.2	172 19.3
JUL-2024	890	270 30.3	176 19.8	78 8.8	194 21.8	172 19.3
AUG-2024	879	272 30.9	174 19.8	78 8.9	187 21.3	171 19.5
SEP-2024	886	275 31.0	172 19.4	76 8.6	185 20.9	179 20.2
OCT-2024	871	283 32.5	168 19.3	72 8.3	177 20.3	175 20.1
NOV-2024	850	287 33.8	162 19.1	70 8.2	159 18.7	173 20.4
DEC-2024	844	303 35.9	156 18.5	71 8.4	149 17.7	167 19.8
JAN-2025	844	309 36.6	157 18.6	67 7.9	143 16.9	172 20.4
FEB-2025	834	306 36.7	156 18.7	64 7.7	136 16.3	173 20.7
MAR-2025	823	311 37.8	147 17.9	62 7.5	132 16.0	173 21.0

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
March 2020 - March 2025






1.11 Number of Participants on Integrase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	bictegravir n %	cabotegravir n %	dolutegravir n %	elvitegravir n %	raltegravir n %
APR-2023	6103	3084 50.5	0 0.0	2498 40.9	258 4.2	274 4.5
MAY-2023	6151	3138 51.0	3 0.1	2504 40.7	250 4.1	278 4.5
JUN-2023	6204	3197 51.5	5 0.1	2509 40.4	248 4.0	267 4.3
JUL-2023	6201	3218 51.9	5 0.1	2499 40.3	247 4.0	256 4.1
AUG-2023	6240	3258 52.2	7 0.1	2495 40.0	245 3.9	253 4.1
SEP-2023	6263	3289 52.5	8 0.1	2500 39.9	238 3.8	249 4.0
OCT-2023	6294	3298 52.4	7 0.1	2523 40.1	241 3.8	248 3.9
NOV-2023	6311	3327 52.7	9 0.1	2518 39.9	233 3.7	244 3.9
DEC-2023	6330	3365 53.2	13 0.2	2506 39.6	226 3.6	237 3.7
JAN-2024	6389	3418 53.5	16 0.3	2520 39.4	224 3.5	234 3.7
FEB-2024	6417	3453 53.8	15 0.2	2516 39.2	219 3.4	231 3.6
MAR-2024	6435	3498 54.4	17 0.3	2500 38.9	220 3.4	225 3.5
APR-2024	6483	3545 54.7	17 0.3	2497 38.5	216 3.3	225 3.5
MAY-2024	6511	3586 55.1	19 0.3	2488 38.2	213 3.3	222 3.4
JUN-2024	6528	3614 55.4	21 0.3	2488 38.1	207 3.2	218 3.3
JUL-2024	6584	3650 55.4	25 0.4	2500 38.0	212 3.2	213 3.2
AUG-2024	6593	3683 55.9	26 0.4	2487 37.7	204 3.1	207 3.1
SEP-2024	6610	3700 56.0	32 0.5	2495 37.8	200 3.0	205 3.1
OCT-2024	6680	3757 56.2	34 0.5	2508 37.5	198 3.0	199 3.0
NOV-2024	6681	3791 56.7	33 0.5	2487 37.2	191 2.9	193 2.9
DEC-2024	6720	3819 56.8	33 0.5	2521 37.5	185 2.8	187 2.8
JAN-2025	6762	3866 57.2	36 0.5	2525 37.3	185 2.7	179 2.7
FEB-2025	6754	3883 57.5	41 0.6	2495 36.9	183 2.7	176 2.6
MAR-2025	6767	3913 57.8	48 0.7	2481 36.7	181 2.7	175 2.6

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
March 2020 - March 2025






1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT

MON-YYYY	Total Participants	fostemsavir		maraviroc		lenacapavir	
		n	%	n	%	n	%
APR-2023	20	2	10.0	18	90.0	0	0.0
MAY-2023	20	2	10.0	18	90.0	0	0.0
JUN-2023	20	2	10.0	18	90.0	0	0.0
JUL-2023	20	2	10.0	18	90.0	0	0.0
AUG-2023	20	2	10.0	18	90.0	0	0.0
SEP-2023	20	2	10.0	18	90.0	0	0.0
OCT-2023	20	2	10.0	18	90.0	1	5.0
NOV-2023	19	1	5.3	17	89.5	1	5.3
DEC-2023	19	2	10.5	16	84.2	1	5.3
JAN-2024	21	2	9.5	18	85.7	1	4.8
FEB-2024	21	2	9.5	18	85.7	1	4.8
MAR-2024	21	3	14.3	17	81.0	2	9.5
APR-2024	22	2	9.1	18	81.8	2	9.1
MAY-2024	19	2	10.5	15	79.0	2	10.5
JUN-2024	21	2	9.5	17	81.0	2	9.5
JUL-2024	21	2	9.5	17	81.0	2	9.5
AUG-2024	21	2	9.5	17	81.0	2	9.5
SEP-2024	20	2	10.0	16	80.0	2	10.0
OCT-2024	20	2	10.0	15	75.0	3	15.0
NOV-2024	20	2	10.0	16	80.0	2	10.0
DEC-2024	20	2	10.0	16	80.0	2	10.0
JAN-2025	20	2	10.0	16	80.0	2	10.0
FEB-2025	19	2	10.5	15	79.0	2	10.5
MAR-2025	19	2	10.5	15	79.0	2	10.5

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Both lenacapavir and fostemsavir are currently not on BC-CfE Formulary



1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals
March 2020 - March 2025




1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals

MON-YYYY	Total Participants	1 drug		2 drugs		3 drugs		4 drugs		5 or more drugs	
		n	%	n	%	n	%	n	%	n	%
APR-2023	7553	2	0.0	763	10.1	6307	83.5	440	5.8	41	0.5
MAY-2023	7592	2	0.0	800	10.5	6314	83.2	435	5.7	41	0.5
JUN-2023	7599	2	0.0	819	10.8	6299	82.9	438	5.8	41	0.5
JUL-2023	7577	2	0.0	842	11.1	6253	82.5	440	5.8	40	0.5
AUG-2023	7600	2	0.0	864	11.4	6240	82.1	448	5.9	46	0.6
SEP-2023	7609	2	0.0	879	11.6	6250	82.1	432	5.7	46	0.6
OCT-2023	7610	2	0.0	897	11.8	6237	82.0	433	5.7	41	0.5
NOV-2023	7612	2	0.0	918	12.1	6210	81.6	441	5.8	41	0.5
DEC-2023	7603	2	0.0	936	12.3	6191	81.4	434	5.7	40	0.5
JAN-2024	7642	2	0.0	952	12.5	6214	81.3	432	5.7	42	0.6
FEB-2024	7647	3	0.0	971	12.7	6198	81.1	436	5.7	39	0.5
MAR-2024	7636	2	0.0	991	13.0	6159	80.7	440	5.8	44	0.6
APR-2024	7670	2	0.0	1001	13.1	6184	80.6	437	5.7	46	0.6
MAY-2024	7687	2	0.0	1024	13.3	6188	80.5	434	5.7	39	0.5
JUN-2024	7687	1	0.0	1034	13.5	6181	80.4	429	5.6	42	0.6
JUL-2024	7718	2	0.0	1061	13.8	6184	80.1	434	5.6	37	0.5
AUG-2024	7709	2	0.0	1082	14.0	6155	79.8	431	5.6	39	0.5
SEP-2024	7697	2	0.0	1125	14.6	6101	79.3	426	5.5	43	0.6
OCT-2024	7725	1	0.0	1169	15.1	6087	78.8	427	5.5	41	0.5
NOV-2024	7703	1	0.0	1177	15.3	6069	78.8	417	5.4	39	0.5
DEC-2024	7720	2	0.0	1200	15.5	6054	78.4	424	5.5	40	0.5
JAN-2025	7739	2	0.0	1235	16.0	6047	78.1	416	5.4	39	0.5
FEB-2025	7696	2	0.0	1265	16.4	5977	77.7	414	5.4	38	0.5
MAR-2025	7689	4	0.1	1292	16.8	5942	77.3	414	5.4	37	0.5

n is the number of individual drugs in antiretroviral treatment regimen (excluding low dose ritonavir and cobicistat used for pharmacokinetic boosting)



1.16 Percent Distribution of Active Participants by CD4 Count
March 2020 - March 2025





1.17 Distribution of Active Participants by CD4 Count

Month	# of Pts with CD4: Unreported	# of Pts with CD4: < 200	# of Pts with CD4: 200 - 349	# of Pts with CD4: 350 - 500	# of Pts with CD4: > 500
APR-2023	1140	244	528	989	3836
MAY-2023	1180	251	549	961	3837
JUN-2023	1199	247	554	963	3827
JUL-2023	1233	239	578	927	3805
AUG-2023	1277	254	560	943	3767
SEP-2023	1330	243	547	951	3744
OCT-2023	1380	242	543	943	3727
NOV-2023	1416	237	542	937	3689
DEC-2023	1459	237	530	917	3703
JAN-2024	1496	238	529	916	3679
FEB-2024	1535	242	503	911	3673
MAR-2024	1567	255	498	924	3649
APR-2024	1612	253	486	944	3627
MAY-2024	1647	248	486	923	3661
JUN-2024	1686	247	493	886	3679
JUL-2024	1748	248	493	912	3681
AUG-2024	1793	251	491	910	3659
SEP-2024	1812	241	489	935	3638
OCT-2024	1847	243	499	948	3624
NOV-2024	1882	234	505	917	3652
DEC-2024	1911	232	508	928	3658
JAN-2025	1940	233	509	939	3650
FEB-2025	1959	223	511	930	3640
MAR-2025	1981	225	508	934	3620


CD4 value (cells/μL) as per the most recent test within the past 12 months

CD4 Unreported: CD4 not tested or reported within the past 12 months

Active Participants are participants with antiretroviral treatment in the month based on dispensing record



1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment
March 2020 - March 2025






1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
APR-2023	10	9	90.0	0	0.0	0	0.0	0	0.0	1	10.0	0	0.0
MAY-2023	14	13	92.9	0	0.0	0	0.0	0	0.0	1	7.1	0	0.0
JUN-2023	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUL-2023	11	8	72.7	0	0.0	0	0.0	0	0.0	3	27.3	0	0.0
AUG-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
SEP-2023	5	5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2023	10	9	90.0	0	0.0	0	0.0	1	10.0	0	0.0	0	0.0
NOV-2023	9	7	77.8	0	0.0	0	0.0	1	11.1	1	11.1	0	0.0
DEC-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
JAN-2024	11	9	81.8	0	0.0	0	0.0	0	0.0	2	18.2	0	0.0
FEB-2024	11	11	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2024	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
APR-2024	20	18	90.0	0	0.0	0	0.0	0	0.0	2	10.0	0	0.0
MAY-2024	16	16	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2024	23	22	95.7	0	0.0	0	0.0	0	0.0	1	4.3	0	0.0
JUL-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2024	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NOV-2024	9	8	88.9	0	0.0	1	11.1	0	0.0	0	0.0	0	0.0
DEC-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JAN-2025	14	14	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
FEB-2025	9	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor, **N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor
n is number of participants on the specified regimen category in the specified month
% is ratio of n and total number of participants initiating antiretroviral treatment in the specified month



1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program
March 2020 - March 2025




1.21 Pre-entry CD4 for Antiretroviral Treatment Naive Participants in the HIV Treatment Program

MON-YYYY	# of First Starts	# of Pts with CD4: Unreported		# of Pts with CD4: < 200		# of Pts with CD4: 200 - 349		# of Pts with CD4: 350 - 500		# of Pts with CD4: > 500	
		n	%	n	%	n	%	n	%	n	%
APR-2023	10	1	10.0	3	30.0	1	10.0	1	10.0	4	40.0
MAY-2023	14	3	21.4	3	21.4	2	14.3	5	35.7	1	7.1
JUN-2023	17	0	0.0	6	35.3	3	17.7	2	11.8	6	35.3
JUL-2023	11	0	0.0	3	27.3	3	27.3	2	18.2	3	27.3
AUG-2023	13	2	15.4	3	23.1	4	30.8	2	15.4	2	15.4
SEP-2023	5	0	0.0	2	40.0	0	0.0	0	0.0	3	60.0
OCT-2023	10	1	10.0	1	10.0	3	30.0	2	20.0	3	30.0
NOV-2023	9	1	11.1	2	22.2	0	0.0	2	22.2	4	44.4
DEC-2023	13	1	7.7	1	7.7	3	23.1	0	0.0	8	61.5
JAN-2024	11	1	9.1	4	36.4	2	18.2	1	9.1	3	27.3
FEB-2024	11	1	9.1	3	27.3	4	36.4	2	18.2	1	9.1
MAR-2024	13	2	15.4	5	38.5	1	7.7	1	7.7	4	30.8
APR-2024	20	0	0.0	4	20.0	6	30.0	1	5.0	9	45.0
MAY-2024	16	1	6.3	5	31.3	3	18.8	1	6.3	6	37.5
JUN-2024	23	0	0.0	2	8.7	10	43.5	4	17.4	7	30.4
JUL-2024	10	1	10.0	1	10.0	3	30.0	3	30.0	2	20.0
AUG-2024	15	0	0.0	5	33.3	4	26.7	3	20.0	3	20.0
SEP-2024	7	0	0.0	1	14.3	4	57.1	1	14.3	1	14.3
OCT-2024	15	0	0.0	6	40.0	3	20.0	3	20.0	3	20.0
NOV-2024	9	0	0.0	3	33.3	3	33.3	2	22.2	1	11.1
DEC-2024	10	0	0.0	4	40.0	2	20.0	2	20.0	2	20.0
JAN-2025	14	0	0.0	6	42.9	2	14.3	5	35.7	1	7.1
FEB-2025	9	0	0.0	2	22.2	1	11.1	3	33.3	3	33.3
MAR-2025	12	1	8.3	5	41.7	2	16.7	2	16.7	2	16.7

First Starts defined as participants starting antiretroviral treatment in the specified month for the first time (antiretroviral treatment naive)
Pre-entry CD4 (cells/ μ L) is defined as most recent CD4 test before antiretroviral treatment start

1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment
March 2020 - March 2025



1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment

MON-YYYY	On Antiretroviral (ARV) Treatment	Ever Tested	NNRTI		N(t)RTI		PI		INSTI	
			n	%	n	%	n	%	n	%
APR-2023	7531	6416	1332	20.8	1674	26.1	566	8.8	99	1.5
MAY-2023	7574	6449	1329	20.6	1681	26.1	563	8.7	106	1.6
JUN-2023	7577	6441	1312	20.4	1672	26.0	561	8.7	106	1.7
JUL-2023	7555	6417	1313	20.5	1678	26.2	563	8.8	106	1.7
AUG-2023	7577	6417	1313	20.5	1663	25.9	557	8.7	107	1.7
SEP-2023	7579	6402	1304	20.4	1644	25.7	557	8.7	104	1.6
OCT-2023	7579	6390	1307	20.5	1647	25.8	552	8.6	99	1.6
NOV-2023	7578	6384	1307	20.5	1643	25.7	558	8.7	101	1.6
DEC-2023	7574	6370	1306	20.5	1633	25.6	553	8.7	100	1.6
JAN-2024	7613	6395	1306	20.4	1644	25.7	549	8.6	102	1.6
FEB-2024	7620	6405	1301	20.3	1646	25.7	562	8.8	102	1.6
MAR-2024	7616	6389	1294	20.3	1637	25.6	555	8.7	105	1.6
APR-2024	7647	6407	1299	20.3	1636	25.5	563	8.8	102	1.6
MAY-2024	7666	6415	1301	20.3	1636	25.5	566	8.8	103	1.6
JUN-2024	7678	6415	1306	20.4	1625	25.3	560	8.7	101	1.6
JUL-2024	7697	6421	1315	20.5	1635	25.5	557	8.7	107	1.7
AUG-2024	7686	6406	1304	20.4	1619	25.3	547	8.5	105	1.6
SEP-2024	7674	6387	1299	20.3	1621	25.4	553	8.7	102	1.6
OCT-2024	7702	6404	1285	20.1	1617	25.3	555	8.7	99	1.6
NOV-2024	7674	6370	1279	20.1	1613	25.3	544	8.5	97	1.5
DEC-2024	7693	6369	1279	20.1	1600	25.1	541	8.5	101	1.6
JAN-2025	7712	6370	1272	20.0	1587	24.9	529	8.3	105	1.7
FEB-2025	7673	6324	1268	20.1	1574	24.9	530	8.4	106	1.7
MAR-2025	7668	6323	1259	19.9	1560	24.7	531	8.4	108	1.7

On Antiretroviral (ARV) Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever Tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the month of interest.

n: number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug in the corresponding drug class in BC. Participants may have resistance to none or 1 or more drug class(es).

% is calculated as ratio of "n" and number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug the corresponding drug class in BC.


Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8. HIVdb scores ≥ 15 are classified as "resistant".

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance
March 2020 - March 2025



1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance

MON-YYYY	On Antiretroviral Treatment	Ever Tested	0-Class (Wild Type)		1-Class		2-Class		3 or more Class	
			n	%	n	%	n	%	n	%
APR-2023	7531	6416	4082	63.6	1281	20.0	773	12.1	280	4.4
MAY-2023	7574	6449	4102	63.6	1296	20.1	774	12.0	277	4.3
JUN-2023	7577	6441	4109	63.8	1294	20.1	761	11.8	277	4.3
JUL-2023	7555	6417	4084	63.6	1289	20.1	765	11.9	279	4.4
AUG-2023	7577	6417	4094	63.8	1286	20.0	761	11.9	276	4.3
SEP-2023	7579	6402	4095	64.0	1280	20.0	755	11.8	272	4.3
OCT-2023	7579	6390	4083	63.9	1281	20.1	758	11.9	268	4.2
NOV-2023	7578	6384	4073	63.8	1287	20.2	754	11.8	270	4.2
DEC-2023	7574	6370	4067	63.9	1286	20.2	749	11.8	268	4.2
JAN-2024	7613	6395	4084	63.9	1292	20.2	751	11.7	268	4.2
FEB-2024	7620	6405	4095	63.9	1284	20.1	755	11.8	271	4.2
MAR-2024	7616	6389	4093	64.1	1276	20.0	749	11.7	271	4.2
APR-2024	7647	6407	4100	64.0	1291	20.2	743	11.6	273	4.3
MAY-2024	7666	6415	4104	64.0	1291	20.1	749	11.7	271	4.2
JUN-2024	7678	6415	4114	64.1	1285	20.0	743	11.6	273	4.3
JUL-2024	7697	6421	4107	64.0	1293	20.1	746	11.6	275	4.3
AUG-2024	7686	6406	4112	64.2	1287	20.1	737	11.5	270	4.2
SEP-2024	7674	6387	4095	64.1	1285	20.1	735	11.5	272	4.3
OCT-2024	7702	6404	4117	64.3	1287	20.1	734	11.5	266	4.2
NOV-2024	7674	6370	4095	64.3	1281	20.1	732	11.5	262	4.1
DEC-2024	7693	6369	4101	64.4	1276	20.0	733	11.5	259	4.1
JAN-2025	7712	6370	4112	64.6	1276	20.0	731	11.5	251	3.9
FEB-2025	7673	6324	4075	64.4	1273	20.1	724	11.5	252	4.0
MAR-2025	7668	6323	4083	64.6	1275	20.2	715	11.3	250	4.0

Number of Antiretroviral (ARV) Drug Classes with Resistance considers N(t)RTIs, NNRTIs, PIs, and INSTIs only, based on cumulative resistance tests performed in BC (until the specified month) for participants ever tested (see definition below).

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.

HIVdb scores ≥ 15 are classified as "resistant".

On Antiretroviral Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the specified month.





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of March 2025

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
Pre-1993	31	46	181	172	9	34	(30, 39)	93	570	(410, 790)	165	<40	(<40, <40)
1993	29	118	119	106	13	34	(29, 39)	73	630	(420, 820)	108	<40	(<40, <40)
1994	28	74	74	62	12	34	(29, 37)	46	575	(363, 815)	64	<40	(<40, <40)
1995	28	126	127	109	18	34	(29, 39)	78	590	(415, 778)	119	<40	(<40, <40)
1996	26	317	319	274	45	35	(30, 39)	183	620	(425, 840)	286	<40	(<40, <40)
1997	24	264	270	246	24	34	(30, 38)	166	600	(390, 845)	241	<40	(<40, <40)
1998	23	186	195	163	32	34	(31, 40)	130	610	(420, 818)	169	<40	(<40, <40)
1999	23	170	171	133	38	36	(30, 42)	121	580	(380, 830)	151	<40	(<40, <40)
2000	24	124	127	102	25	38	(34, 44)	82	615	(375, 775)	115	<40	(<40, <40)
2001	23	119	122	99	23	37	(30, 44)	76	650	(425, 813)	109	<40	(<40, <40)
2002	22	117	126	107	19	40	(30, 46)	77	520	(410, 740)	112	<40	(<40, <40)
2003	21	141	151	127	24	39	(34, 46)	101	610	(430, 810)	132	<40	(<40, <40)
2004	20	143	166	130	36	40	(34, 44)	110	655	(458, 875)	142	<40	(<40, <40)
2005	19	181	198	159	39	41	(35, 47)	139	620	(430, 880)	180	<40	(<40, <40)
2006	18	178	197	157	40	41	(33, 48)	139	600	(445, 800)	173	<40	(<40, <40)
2007	17	236	254	219	35	41	(35, 46)	178	670	(470, 880)	222	<40	(<40, <40)
2008	16	276	310	253	57	42	(35, 49)	222	685	(500, 936)	278	<40	(<40, <40)
2009	15	303	335	274	61	41	(35, 47)	226	669	(480, 904)	312	<40	(<40, <40)
2010	14	260	300	237	63	40	(32, 46)	213	660	(460, 860)	262	<40	(<40, <40)
2011	13	317	362	295	67	42	(34, 48)	234	710	(490, 900)	318	<40	(<40, <40)
2012	12	278	316	254	62	41	(32, 49)	194	730	(530, 1010)	280	<40	(<40, <40)
2013	12	248	293	236	57	40	(32, 49)	196	695	(460, 900)	253	<40	(<40, <40)
2014	11	231	299	256	43	39	(31, 50)	187	750	(535, 980)	258	<40	(<40, <40)
2015	10	199	284	242	42	41	(32, 51)	195	700	(500, 920)	247	<40	(<40, <40)
2016	9	179	254	209	45	38	(32, 49)	172	655	(480, 885)	222	<40	(<40, <40)
2017	8	158	223	191	32	36	(28, 45)	157	680	(490, 860)	199	<40	(<40, <40)
2018	7	133	204	163	41	39	(31, 48)	142	766	(565, 988)	174	<40	(<40, <40)
2019	6	133	247	207	40	38	(29, 48)	185	740	(480, 940)	222	<40	(<40, <40)
2020	5	104	200	149	51	37	(31, 48)	151	760	(535, 960)	169	<40	(<40, <40)

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
 CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of March 2025 (cont.)

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
2021	4	112	206	174	32	38	(29, 46)	184	675	(493, 910)	146	<40	(<40, <40)
2022	3	111	274	223	51	38	(31, 47)	250	690	(510, 900)	210	<40	(<40, <40)
2023	2	114	313	257	56	35	(30, 45)	293	610	(430, 815)	239	<40	(<40, <40)
2024	1	137	362	290	72	36	(29, 45)	342	610	(430, 830)	334	<40	(<40, <40)
2025	0	34	89	69	20	36	(30, 42)	87	575	(323, 795)	83	<40	(<40, 92)
Total:		5867	7668	6344	1324								

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively



2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment

MON-YYYY	Total Participants	Median # of Treatment days	(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
				Median	(Q1, Q3)		Median	(Q1, Q3)
APR-2023	7553	796	5597	640	(460, 860)	6836	<40	(<40, <40)
MAY-2023	7592	786	5598	640	(451, 860)	6873	<40	(<40, <40)
JUN-2023	7599	787	5591	640	(450, 860)	6918	<40	(<40, <40)
JUL-2023	7577	805	5549	650	(450, 860)	6937	<40	(<40, <40)
AUG-2023	7600	804	5524	641	(450, 860)	6890	<40	(<40, <40)
SEP-2023	7609	796	5485	650	(450, 860)	6893	<40	(<40, <40)
OCT-2023	7610	803	5455	640	(450, 860)	6812	<40	(<40, <40)
NOV-2023	7612	795	5405	640	(450, 860)	6840	<40	(<40, <40)
DEC-2023	7603	798	5387	650	(460, 860)	6828	<40	(<40, <40)
JAN-2024	7642	792	5362	640	(460, 860)	6814	<40	(<40, <40)
FEB-2024	7647	781	5329	650	(460, 870)	6864	<40	(<40, <40)
MAR-2024	7636	790	5326	640	(450, 870)	6871	<40	(<40, <40)
APR-2024	7670	786	5310	640	(450, 870)	6842	<40	(<40, <40)
MAY-2024	7687	787	5318	650	(460, 880)	6896	<40	(<40, <40)
JUN-2024	7687	784	5305	650	(460, 870)	6921	<40	(<40, <40)
JUL-2024	7718	786	5334	650	(460, 870)	7009	<40	(<40, <40)
AUG-2024	7709	782	5311	650	(460, 870)	6937	<40	(<40, <40)
SEP-2024	7697	791	5303	650	(460, 870)	6904	<40	(<40, <40)
OCT-2024	7725	787	5314	650	(460, 870)	6898	<40	(<40, <40)
NOV-2024	7703	793	5308	650	(460, 880)	6875	<40	(<40, <40)
DEC-2024	7720	796	5326	650	(460, 880)	6913	<40	(<40, <40)
JAN-2025	7739	792	5331	650	(450, 880)	6882	<40	(<40, <40)
FEB-2025	7696	800	5304	650	(460, 880)	6870	<40	(<40, <40)
MAR-2025	7689	792	5287	650	(450, 875)	6812	<40	(<40, <40)

Active participant defined as being on antiretroviral treatment in the specified month

Treatment days defined as number of consecutive days on antiretroviral treatment (most recent uninterrupted period)

CD4 and pVL tests defined as tests done in the specified month





2.3 BC-CfE HIV Treatment Program Enrolment

MON-YYYY	On ARV Treatment	Off ARV Treatment	Deceased	ARV Treatment naïve starts	ARV Treatment experienced starts	Newly interrupted ARV Treatment	Net Change
APR-2023	7531	748	13	10	177	169	-1
MAY-2023	7574	714	7	14	206	165	43
JUN-2023	7577	697	14	17	168	165	3
JUL-2023	7555	728	11	11	164	181	-22
AUG-2023	7577	727	11	13	217	192	22
SEP-2023	7579	714	14	5	179	163	2
OCT-2023	7579	724	18	10	170	160	0
NOV-2023	7578	731	18	9	182	171	-1
DEC-2023	7574	740	14	13	169	169	-4
JAN-2024	7613	698	16	11	204	159	39
FEB-2024	7620	695	17	11	184	165	7
MAR-2024	7616	709	12	13	183	185	-4
APR-2024	7647	692	17	20	197	168	31
MAY-2024	7666	691	12	16	191	173	19
JUN-2024	7678	706	5	23	173	177	12
JUL-2024	7697	695	15	10	185	159	19
AUG-2024	7686	710	13	15	164	168	-11
SEP-2024	7674	716	9	7	182	186	-12
OCT-2024	7702	709	8	15	200	172	28
NOV-2024	7674	746	14	9	181	199	-28
DEC-2024	7693	743	15	10	194	170	19
JAN-2025	7712	716	14	14	196	170	19
FEB-2025	7673	759	10	9	166	201	-39
MAR-2025	7668	759	12	12	175	177	-5

ARV: antiretroviral

On ARV Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program

Off ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month and not deceased or moved out of program

Deceased: in the specified month, and on ARV treatment in the previous month

ARV Treatment naïve starts: participants starting ARV treatment in the specified month for the first time

ARV Treatment experienced starts: participants with history of ARV treatment, but first dispensing in the BC HIV Treatment Program in the specified month

Newly Interrupted ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month, but had a record of ARV medication in the previous month, and not deceased or moved out of program, and had contact with the program in the past 5 years.


Net Change: the difference between ARV treatment starts (naïve and experienced) and ARV treatment stops (Deceased, moved out of program, or newly interrupted ARV treatment)





3.1 Distribution of HIV Treatment Program Active Participants March 2025

BY HEALTH SERVICE DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV Treatment Program Active Participants March 2025

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV Treatment Program Active Participants
March 2025

FRASER HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE




3.4 Distribution of HIV Treatment Program Active Participants
March 2025

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE



*** Please refer to VIHA (432 and 434) on the next page







3.5 Distribution of HIV Treatment Program Active Participants March 2025



VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA

N = 1061



VICTORIA BY POSTAL CODE


N = 519






3.6 Distribution of HIV Treatment Program Active Participants
March 2025

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE



4.1 Distribution of Participants by Age & Sex at Birth INTERIOR Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	0 - 29	*	*	0	0	N/A	*	*
	30 - 49	*	*	0	11	840	*	*
	50 - 64	*	*	0	14	750	*	*
	65+	*	*	0	7	650	*	*
	Total HSDA:	37	32	0	32	765	31	<40
KOOTENAY BOUNDARY	0 - 29	5	5	0	*	*	*	*
	30 - 49	14	13	0	*	*	*	*
	50 - 64	22	19	0	*	*	*	*
	65+	16	16	0	*	*	*	*
	Total HSDA:	57	53	0	44	710	46	<40
OKANAGAN	0 - 29	14	14	0	15	800	14	<40
	30 - 49	124	113	0	114	705	94	<40
	50 - 64	164	154	0	145	680	131	<40
	65+	80	77	0	75	540	72	<40
	Total HSDA:	382	358	0	349	650	311	<40
THOMPSON/CARIBOO/SHUSWAP	0 - 29	13	12	*	11	600	12	<40
	30 - 49	56	44	*	42	750	43	<40
	50 - 64	86	76	*	70	680	67	<40
	65+	36	37	*	28	715	31	<40
	Total HSDA:	191	169	<5	151	690	153	<40
Total HA:		667	612	<5	576	680	541	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	33	32	*	30	760	31	<40
	30 - 49	209	183	*	177	740	161	<40
	50 - 64	286	260	*	247	680	227	<40
	65+	139	137	*	122	580	122	<40
Total HA:		667	612	<5	576	680	541	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	539	494	*	460	670	433	<40
Female	128	118	*	116	710	108	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	612	56	680	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



4.2 Distribution of Participants by Program Duration INTERIOR Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	10 years or more	16	14	0	14	710	13	<40
	5 years or more	10	8	0	8	835	8	<40
	<5 years	11	10	0	10	845	10	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	37	32	0	32	765	31	<40
KOOTENAY BOUNDARY	10 years or more	41	40	0	32	660	33	<40
	5 years or more	9	6	0	5	780	6	<40
	<5 years	7	7	0	7	750	7	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	57	53	0	44	710	46	<40
OKANAGAN	10 years or more	243	233	0	*	*	*	*
	5 years or more	62	55	0	*	*	*	*
	<5 years	77	70	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	Total HSDA:	382	358	0	349	650	311	<40
THOMPSON/CARIBOO/SHUSWAP	10 years or more	120	108	*	*	*	*	*
	5 years or more	25	19	*	*	*	*	*
	<5 years	46	42	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	191	169	<5	151	690	153	<40
Total HA:		667	612	<5	576	680	541	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	420	395	*	*	*	*	*
	5 years or more	106	88	*	*	*	*	*
	<5 years	141	129	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
Total HA:		667	612	<5	576	680	541	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.3 Distribution of Antiretroviral Treatment Prescribers INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
EAST KOOTENAY	13	33	53	103
KOOTENAY BOUNDARY	18	41	76	140
OKANAGAN	55	333	245	1109
THOMPSON/CARIBOO/SHUSWAP	31	139	152	591
Total:	117	546	526	1943

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	126

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.4 Distribution of Participants by Age & Sex at Birth FRASER Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	0 - 29	33	27	*	29	750	33	<40
	30 - 49	106	86	*	84	693.5	83	<40
	50 - 64	156	143	*	109	600	131	<40
	65+	73	72	*	48	755	66	<40
	Total HSDA:	368	328	<5	270	680	313	<40
FRASER NORTH	0 - 29	49	43	*	44	580	44	<40
	30 - 49	371	332	*	300	720	321	<40
	50 - 64	363	337	*	247	720	320	<40
	65+	169	160	*	106	655	145	<40
	Total HSDA:	952	872	<5	697	690	830	<40
FRASER SOUTH	0 - 29	67	63	*	60	607	64	<40
	30 - 49	356	325	*	256	700	317	<40
	50 - 64	397	371	*	263	630	342	<40
	65+	163	157	*	112	575	153	<40
	Total HSDA:	983	916	<5	691	650	876	<40
Total HA:		2303	2116	<5	1658	670	2019	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	149	133	*	133	659	141	<40
	30 - 49	833	743	*	640	700	721	<40
	50 - 64	916	851	*	619	650	793	<40
	65+	405	389	*	266	615	364	<40
Total HA:		2303	2116	<5	1658	670	2019	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	1743	1614	*	1206	653	1537	<40
Female	560	502	*	452	720	482	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	2116	53	680	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.5 Distribution of Participants by Program Duration FRASER Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	10 years or more	236	219	*	*	*	*	*
	5 years or more	56	40	*	*	*	*	*
	<5 years	76	69	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	368	328	<5	270	680	313	<40
FRASER NORTH	10 years or more	591	550	*	403	730	*	*
	5 years or more	171	154	*	132	715	*	*
	<5 years	190	168	*	162	610	*	*
	Never on ART	0	0	*	0	N/A	*	*
	Total HSDA:	952	872	<5	697	690	830	<40
FRASER SOUTH	10 years or more	574	528	*	*	*	*	*
	5 years or more	175	158	*	*	*	*	*
	<5 years	234	230	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	983	916	<5	691	650	876	<40
Total HA:		2303	2116	<5	1658	670	2019	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	1401	1297	*	952	690	1212	<40
	5 years or more	402	352	*	285	690	336	<40
	<5 years	500	467	*	416	620	466	<40
	Never on ART	0	0	*	5	670	5	<40
Total HA:		2303	2116	<5	1658	670	2019	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.6 Distribution of Antiretroviral Treatment Prescribers FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
FRASER EAST	30	66	154	555
FRASER NORTH	32	245	268	1654
FRASER SOUTH	42	550	237	1959
Total:	104	861	659	4168

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
FRASER EAST	217
FRASER NORTH	713
FRASER SOUTH	486
Total:	1416

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.7 Distribution of Participants by Age & Sex at Birth VANCOUVER COASTAL Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	0 - 29	12	11	0	10	900	11	<40
	30 - 49	81	77	0	62	695	67	<40
	50 - 64	130	119	0	79	730	104	<40
	65+	95	90	0	76	655	83	<40
	Total HSDA:	318	297	0	227	700	265	<40
RICHMOND	0 - 29	12	8	0	12	610	10	<40
	30 - 49	65	60	0	56	620	56	<40
	50 - 64	75	70	0	57	610	71	<40
	65+	29	29	0	25	537	27	<40
	Total HSDA:	181	167	0	150	605	164	<40
VANCOUVER	0 - 29	109	96	*	95	730	100	<40
	30 - 49	1138	993	*	819	690	966	<40
	50 - 64	1519	1395	*	1041	610	1348	<40
	65+	728	692	*	453	610	687	<40
	Total HSDA:	3494	3176	<5	2408	640	3101	<40
Total HA:		3993	3640	<5	2785	650	3530	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	133	115	*	117	730	121	<40
	30 - 49	1284	1130	*	937	690	1089	<40
	50 - 64	1724	1584	*	1177	620	1523	<40
	65+	852	811	*	554	610	797	<40
Total HA:		3993	3640	<5	2785	650	3530	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	3500	3191	*	2335	650	3117	<40
Female	493	449	*	450	645	413	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	3640	56	650	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.8 Distribution of Participants by Program Duration VANCOUVER COASTAL Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	10 years or more	228	211	0	*	*	*	*
	5 years or more	44	43	0	*	*	*	*
	<5 years	46	43	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	Total HSDA:	318	297	0	227	700	265	<40
RICHMOND	10 years or more	100	94	0	75	590	93	<40
	5 years or more	35	30	0	29	610	26	<40
	<5 years	46	43	0	46	600	45	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	181	167	0	150	605	164	<40
VANCOUVER	10 years or more	2442	2261	*	*	*	*	*
	5 years or more	557	468	*	*	*	*	*
	<5 years	495	447	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	3494	3176	<5	2408	640	3101	<40
Total HA:		3993	3640	<5	2785	650	3530	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	2770	2566	*	*	*	*	*
	5 years or more	636	541	*	*	*	*	*
	<5 years	587	533	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
Total HA:		3993	3640	<5	2785	650	3530	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.9 Distribution of Antiretroviral Treatment Prescribers VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH SHORE/COAST GARIBALDI	37	58	200	580
RICHMOND	9	113	49	340
VANCOUVER	207	5407	696	12171
Total:	253	5578	945	13091

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	61

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.10 Distribution of Participants by Age & Sex at Birth VANCOUVER ISLAND Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	0 - 29	8	6	0	*	*	7	<40
	30 - 49	80	76	0	*	*	68	<40
	50 - 64	144	133	0	*	*	111	<40
	65+	84	81	0	*	*	74	<40
	Total HSDA:	316	296	0	177	570	260	<40
NORTH VANCOUVER ISLAND	0 - 29	5	5	0	5	760	*	*
	30 - 49	29	24	0	19	590	*	*
	50 - 64	54	53	0	27	520	*	*
	65+	34	31	0	16	615	*	*
	Total HSDA:	122	113	0	67	610	89	<40
SOUTH VANCOUVER ISLAND	0 - 29	27	25	*	12	555	18	<40
	30 - 49	209	179	*	74	670	154	<40
	50 - 64	313	292	*	91	640	249	<40
	65+	160	156	*	39	680	141	<40
	Total HSDA:	709	652	<5	216	655	562	<40
Total HA:		1147	1061	<5	460	610	911	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	40	36	*	21	690	29	<40
	30 - 49	318	279	*	147	630	239	<40
	50 - 64	511	478	*	192	635	402	<40
	65+	278	268	*	100	590	241	<40
Total HA:		1147	1061	<5	460	610	911	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	957	885	*	363	600	754	<40
Female	190	176	*	97	690	157	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	1061	57	620	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART:** # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.11 Distribution of Participants by Program Duration VANCOUVER ISLAND Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	10 years or more	214	201	0	106	580	169	<40
	5 years or more	55	51	0	36	590	44	<40
	<5 years	47	44	0	35	560	47	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	316	296	0	177	570	260	<40
NORTH VANCOUVER ISLAND	10 years or more	89	82	0	42	525	64	<40
	5 years or more	14	13	0	7	570	10	<40
	<5 years	19	18	0	18	690	15	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	122	113	0	67	610	89	<40
SOUTH VANCOUVER ISLAND	10 years or more	433	404	*	*	*	*	*
	5 years or more	133	116	*	*	*	*	*
	<5 years	143	132	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	709	652	<5	216	655	562	<40
Total HA:		1147	1061	<5	460	610	911	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	736	687	*	*	*	*	*
	5 years or more	202	180	*	*	*	*	*
	<5 years	209	194	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
Total HA:		1147	1061	<5	460	610	911	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.12 Distribution of Antiretroviral Treatment Prescribers VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
CENTRAL VANCOUVER ISLAND	69	214	215	979
NORTH VANCOUVER ISLAND	33	70	155	367
SOUTH VANCOUVER ISLAND	46	609	237	2070
Total:	148	893	607	3416

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
CENTRAL VANCOUVER ISLAND	86
NORTH VANCOUVER ISLAND	51
SOUTH VANCOUVER ISLAND	128
Total:	265

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.13 Distribution of Participants by Age & Sex at Birth NORTHERN Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	46	37	0	43	590	37	<40
NORTH WEST	0 - 29	0	0	*	0	N/A	0	N/A
	30 - 49	24	19	*	18	665	18	<40
	50 - 64	35	33	*	32	550	25	<40
	65+	11	9	*	11	550	9	<40
	Total HSDA:	70	61	<5	61	570	52	<40
NORTHERN INTERIOR	0 - 29	8	7	0	8	660	6	<40
	30 - 49	71	56	0	63	630	50	<40
	50 - 64	71	61	0	69	490	55	<40
	65+	30	27	0	30	555	26	<40
	Total HSDA:	180	151	0	170	570	137	<40
Total HA:		296	249	<5	274	570	226	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	12	10	*	12	660	9	<40
	30 - 49	115	89	*	98	635	83	<40
	50 - 64	123	108	*	117	540	94	<40
	65+	46	42	*	47	550	40	<40
Total HA:		296	249	<5	274	570	226	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	195	169	*	184	605	159	<40
Female	101	80	*	90	505	67	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	249	54	570	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.14 Distribution of Participants by Program Duration NORTHERN Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	10 years or more	22	*	0	*	*	*	*
	5 years or more	5	*	0	*	*	*	*
	<5 years	19	*	0	*	*	*	*
	Never on ART	0	*	0	*	*	*	*
	Total HSDA:	46	37	0	43	590	37	<40
NORTH WEST	10 years or more	48	44	*	42	545	34	<40
	5 years or more	9	7	*	7	810	8	<40
	<5 years	13	10	*	12	625	10	<40
	Never on ART	0	0	*	0	N/A	0	N/A
	Total HSDA:	70	61	<5	61	570	52	<40
NORTHERN INTERIOR	10 years or more	112	94	0	108	550	83	<40
	5 years or more	40	33	0	37	620	33	<40
	<5 years	28	24	0	25	640	21	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	180	151	0	170	570	137	<40
Total HA:		296	249	<5	274	570	226	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	182	155	*	170	550	134	<40
	5 years or more	54	43	*	48	625	44	<40
	<5 years	60	51	*	56	625	48	<40
	Never on ART	0	0	*	0	N/A	0	N/A
Total HA:		296	249	<5	274	570	226	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.15 Distribution of Antiretroviral Treatment Prescribers NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH EAST	2	*	37	50
NORTH WEST	15	*	92	175
NORTHERN INTERIOR	23	*	129	552
Total:	40	233	258	777

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH EAST	9
NORTH WEST	26
NORTHERN INTERIOR	25
Total:	60

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth

HA	HSDA	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
INTERIOR	EAST KOOTENAY	*	*	0	*	*	*	*
	KOOTENAY BOUNDARY	*	*	0	*	*	*	*
	OKANAGAN	*	*	0	*	*	*	*
	THOMPSON/CARIBOO/SHUSWAP	*	*	0	*	*	*	*
	Total HA:	50	44	0	43	500	38	<40
FRASER	FRASER EAST	33	26	0	27	690	28	<40
	FRASER NORTH	40	34	0	31	450	34	<40
	FRASER SOUTH	64	58	0	48	555	51	<40
	Total HA:	137	118	0	106	530	113	<40
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	*	*	0	*	*	*	*
	RICHMOND	*	*	0	*	*	*	*
	VANCOUVER	*	*	0	*	*	*	*
	Total HA:	404	375	0	377	510	346	<40
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	44	40	0	24	490	31	<40
	NORTH VANCOUVER ISLAND	16	14	0	12	490	9	<40
	SOUTH VANCOUVER ISLAND	43	40	0	16	570	29	<40
	Total HA:	103	94	0	52	530	69	<40
NORTHERN	NORTH EAST	11	8	0	11	500	7	<40
	NORTH WEST	33	28	0	28	550	24	<40
	NORTHERN INTERIOR	65	53	0	62	565	48	<40
	Total HA:	109	89	0	101	560	79	<40
Total:	803	720	0	679	520	645	<40	

Sex at Birth	# Enrolled	# on Antiretroviral Treatment	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	505	453	0	423	510	407	<40
Female	298	267	0	256	530	238	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total:	720	55	530	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program

on Antiretroviral Treatment: defined as # of Participants being on antiretroviral treatment in the specified month

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)





BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

Funding for the BC Centre for Excellence in HIV/AIDS and HIV Drug Treatment Program provided in-part by:

